CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
Open accessAbstract
Objective— Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein (a)] and is an independent risk factor for cardiovascular disease and aortic stenosis. In clinical trials, anacetrapib, a CETP (cholesteryl ester transfer protein) inhibitor, causes significant reductions in plasma Lp(a) levels. We conducted an exploratory study to examine the mechanism for Lp(a) lowering by anacetrapib. Approach and Results— We enrolled 39 participants in a fixed-sequence, double-blind study of the effects of anacetrapib on the metabolism of apoB and high-density lipoproteins. Twenty-nine patients were randomized to atorvastatin 20 mg/d, plus placebo for 4 weeks, and then atorvastatin plus anacetrapib (100 mg/d) for 8 weeks. The other 10 subjects were randomized to double placebo for 4 weeks followed by placebo plus anacetrapib for 8 weeks. We examined the mechanisms of Lp(a) lowering in a subset of 12 subjects having both Lp(a) levels >20 nmol/L and more than a 15% reduction in Lp(a) by the end of anacetrapib treatment. We performed stable isotope kinetic studies using 2 H 3 -leucine at the end of each treatment to measure apo(a) fractional catabolic rate and production rate. Median baseline Lp(a) levels were 21.5 nmol/L (interquartile range, 9.9–108.1 nmol/L) in the complete cohort (39 subjects) and 52.9 nmol/L (interquartile range, 38.4–121.3 nmol/L) in the subset selected for kinetic studies. Anacetrapib treatment lowered Lp(a) by 34.1% ( P ≤0.001) and 39.6% in the complete and subset cohort, respectively. The decreases in Lp(a) levels were because of a 41% reduction in the apo(a) production rate, with no effects on apo(a) fractional catabolic rate. Conclusions— Anacetrapib reduces Lp(a) levels by decreasing its production. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00990808.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CETP inhibitors, like anacetrapib, have shown promise in reducing Lp(a) levels, primarily through diminishing apo(a) production.
“CETP inhibitors, like anacetrapib, have shown promise in reducing Lp(a) levels, primarily through diminishing apo(a) production [17].”
From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792 · see citing works
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749 · see citing works
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461 · see citing works
Lipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338 · see citing works
Self-citationPackard, C. J., Munro, A. F., Lorimer, A. R., Gotto, A. M., & Shepherd, J. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111644 · Cited by 298 · see citing works
Bloomfield, D. M., Carlson, G. L., Sapre, A., Tribble, D. L., McKenney, J. M., Littlejohn, T. W., Sisk, C. M., Mitchel, Y., & Pasternak, R. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.09.022 · Cited by 242 · see citing works
Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans
Reyes-Soffer, G., Pavlyha, M., Ngai, C., Thomas, T., Holleran, S., Ramakrishnan, R., Karmally, W., Nandakumar, R., Fontanez, N., Obunike, J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.025253 · Cited by 240 · see citing works
Self-citationDifferences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans
Marcovina, S. M., Albers, J. J., Wijsman, E. M., ZHANG, Z., Chapman, N. H., & Kennedy, H. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37461-7 · Cited by 236 · see citing works
Self-citationMarcovina, S. M., Zhang, Z., Gaur, V. P., & Albers, J. J. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1343 · Cited by 225 · see citing works
Self-citationVarvel, S. A., McConnell, J. P., & Tsimikas, S. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308011 · Cited by 219 · see citing works
The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.
Rader, D. J., Mann, W. A., Cain, W. J., Kraft, H. G., Usher, D. C., Zech, L. A., Hoeg, J. M., Davignon, J., Lupien, P. J., & S, M. G. B. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117794 · Cited by 207 · see citing works
Self-citationRader, D. J., Cain, W. J., Zech, L. A., Usher, D. C., & Brewer, H. B. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116221 · Cited by 194 · see citing works
Self-citationEffect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program)
Gaudet, D., Watts, G. F., Robinson, J. G., Minini, P., Sasiela, W. J., Edelberg, J. M., Louie, M. J., & Raal, F. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.09.010 · Cited by 127 · see citing works
Cohen, J. C., Chiesa, G., & Hobbs, H. H. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116370 · Cited by 119 · see citing works
Jiang, X., Masucci-Magoulas, L., Mar, J., Lin, M., Walsh, A., Breslow, J. L., & Tall, A. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)74263-x · Cited by 108 · see citing works
Recycling of Apolipoprotein(a) After PlgRKT-Mediated Endocytosis of Lipoprotein(a)
Sharma, M., Redpath, G., Williams, M. J. A., & McCormick, S. P. A. (2016) · Circulation Research · doi:10.1161/circresaha.116.310272 · Cited by 93 · see citing works
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects
Millar, J. S., Reyes‐Soffer, G., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., Rafeek, H., Pollan, L. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80025 · Cited by 88 · see citing works
Self-citationLipoprotein (a): a historical appraisal
Kostner, K., & Kostner, G. M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r071571 · Cited by 81 · see citing works
Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism
Lamon‐Fava, S., Diffenderfer, M. R., Barrett, P. H. R., Buchsbaum, A., Matthan, N. R., Lichtenstein, A. H., Dolnikowski, G. G., Horvath, K. V., Asztalos, B. F., Zago, V., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700067-jlr200 · Cited by 80 · see citing works
In vivo stable-isotope kinetic study suggests intracellular assembly of lipoprotein(a)
Frischmann, M. E., Ikewaki, K., Trenkwalder, E., Lamina, C., Dieplinger, B., Soufi, M., Schweer, H., Schaefer, J. R., König, P., Kronenberg, F., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.09.031 · Cited by 71 · see citing works
The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beings
Jenner, J. L., SEMAN, L. J., Millar, J. S., Lamon‐Fava, S., Welty, F. K., Dolnikowski, G. G., Marcovina, S. M., Lichtenstein, A. H., Barrett, P. H. R., deLuca, C., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.10.001 · Cited by 68 · see citing works
Self-citationMillar, J. S., Brousseau, M. E., Diffenderfer, M. R., Hugh, P., Barrett, P. H. R., Welty, F. K., Faruqi, A., Wolfe, M. L., Nartsupha, C., DIGENIO, A. G., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000219695.84644.56 · Cited by 64 · see citing works
Self-citationCroyal, M., Ouguerram, K., Passard, M., Ferchaud‐Roucher, V., Chétiveaux, M., Billon‐Crossouard, S., de Gouville, A., Lambert, G. C., Krempf, M., & Nobécourt, E. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305835 · Cited by 62 · see citing works
Su, W., Campos, H., Judge, H., Walsh, B. W., & Sacks, F. M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5116 · Cited by 60 · see citing works
Demant, T., Seeberg, K., Bedynek, A., & Seidel, D. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(00)00732-2 · Cited by 57 · see citing works
Ooi, E. M. M., Watts, G. F., Chan, D. C., Pang, J., Tenneti, V. S., Hamilton, S. J., McCormick, S. P. A., Marcovina, S. M., & Barrett, P. H. R. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306136 · Cited by 54 · see citing works
Self-citationNassir, F., Bonen, D. K., & Davidson, N. O. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.28.17793 · Cited by 53 · see citing works
Relation of Apo(a) Size to Carotid Atherosclerosis in an Elderly Multiethnic Population
Paultre, F., Tuck, C. H., Boden-Albala, B. M., Kargman, D. E., Todd, E., Jones, J., Paik, M. C., Sacco, R. L., & Berglund, L. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0102.101097 · Cited by 53 · see citing works
Apolipoprotein (a) alleles determine lipoprotein (a) particle density and concentration in plasma.
Kraft, H. G., Sandholzer, C., Menzel, H.-J., & Utermann, G. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.3.302 · Cited by 49 · see citing works
An efficient method for accommodating potentially underpowered primary endpoints
Li, J. (., & Mehrotra, D. V. (2008) · Statistics in Medicine · doi:10.1002/sim.3369 · Cited by 46 · see citing works
Reyes‐Soffer, G., Millar, J. S., Ngai, C. I., Jumes, P. A., Coromilas, E. J., Asztalos, B. F., Johnson‐Levonas, A. O., Wagner, J. A., Donovan, D. S., Karmally, W., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306680 · Cited by 38 · see citing works
Self-citationZhou, H., Castro‐Perez, J. M., Lassman, M. E., Thomas, T. A., Li, W., McLaughlin, T. M., Xie, D., Jumes, P. A., Wagner, J. A., Gutstein, D. E., et al. (2013) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6572 · Cited by 31 · see citing works
Self-citationLipoprotein (a): Coming of Age at Last
Witztum, J. L., & Ginsberg, H. N. (2016) · Journal of Lipid Research · doi:10.1194/jlr.e066985 · Cited by 26 · see citing works
Self-citationMillar, J. S., Lassman, M. E., Thomas, T. A., Ramakrishnan, R., Jumes, P. A., Dunbar, R. L., deGoma, E. M., Baer, A. L., Karmally, W., Donovan, D. S., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m074880 · Cited by 21 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Trials and Tribulations of CETP Inhibitors
Tall, A. R., & Rader, D. J. (2017) · Circulation Research · doi:10.1161/circresaha.117.311978 · Cited by 303 · see citing works
Self-citationLipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P. A., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Małyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 275 · see citing works
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Yeang, C., Karwatowska‐Prokopczuk, E., Su, F., Dinh, B., Xia, S., Witztum, J. L., & Tsimikas, S. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.032 · Cited by 216 · see citing works
Nicholls, S. J., Ditmarsch, M., Kastelein, J. J. P., Rigby, S. P., Kling, D. F., Curcio, D. L., Alp, N. J., & Davidson, M. H. (2022) · Nature Medicine · doi:10.1038/s41591-022-01936-7 · Cited by 175 · see citing works
Vuorio, A. F., Watts, G. F., Schneider, W. J., Tsimikas, S., & Kovanen, P. T. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12981 · Cited by 118 · see citing works
Sahebkar, A., Simental‐Mendía, L. E., Pirro, M., Banach, M., Watts, G. F., Sirtori, C. R., Al‐Rasadi, K., & Atkin, S. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-36204-7 · Cited by 105 · see citing works
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93 · see citing works
Self-citationBeyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
Reyes‐Soffer, G., & Westerterp, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105689 · Cited by 92 · see citing works
Self-citationExisting and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 86 · see citing works
Highlighting Residual Atherosclerotic Cardiovascular Disease Risk
Matsuura, Y., Kanter, J. E., & Bornfeldt, K. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311999 · Cited by 85 · see citing works
Lipoprotein(a): Knowns, unknowns and uncertainties
Ruscica, M., Sirtori, C. R., Corsini, A., Watts, G. F., & Sahebkar, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105812 · Cited by 84 · see citing works
Hoekstra, M., Chen, H. Y., Rong, J., Dufresne, L., Yao, J., Guo, X., Tsai, M. Y., Tsimikas, S., Post, W. S., Vasan, R. S., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314965 · Cited by 79 · see citing works
The renaissance of lipoprotein(a): Brave new world for preventive cardiology?
Ellis, K. L., Boffa, M. B., Sahebkar, A., Koschinsky, M. L., & Watts, G. F. (2017) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.09.001 · Cited by 71 · see citing works
Recent advances in demystifying the metabolism of lipoprotein(a)
Chemello, K., Chan, D. C., Lambert, G. C., & Watts, G. F. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.002 · Cited by 64 · see citing works
Nandakumar, R., Matveyenko, A., Thomas, T. A., Pavlyha, M., Ngai, C. I., Holleran, S., Ramakrishnan, R., Ginsberg, H. N., Karmally, W., Marcovina, S. M., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p082834 · Cited by 58 · see citing works
Self-citationSwerdlow, D. I., Rider, D. A., Yavari, A., Lindholm, M., Campion, G., & Nissen, S. E. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab100 · Cited by 58 · see citing works
Present therapeutic role of cholesteryl ester transfer protein inhibitors
Ferri, N., Corsini, A., Sirtori, C. R., & Ruscica, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.028 · Cited by 56 · see citing works
New Frontiers in Lp(a)-Targeted Therapies
Borrelli, M. J., Youssef, A., Boffa, M. B., & Koschinsky, M. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.01.004 · Cited by 53 · see citing works
Kronenberg, F. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_504 · Cited by 53 · see citing works
The Role of High-Density Lipoprotein Cholesterol in 2022
Sirtori, C. R., Corsini, A., & Ruscica, M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01012-y · Cited by 53 · see citing works
Lipoprotein(a) and cardiovascular disease
Boffa, M. B., & Koschinsky, M. L. (2024) · Biochemical Journal · doi:10.1042/bcj20240037 · Cited by 47 · see citing works
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.05.002 · Cited by 46 · see citing works
Enkhmaa, B., & Berglund, L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811297-7.00013-5 · Cited by 44 · see citing works
The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
Phua, K., Chew, N., Kong, W. K. F., Tan, R., Ye, L., & Poh, K. K. (2022) · Theranostics · doi:10.7150/thno.71813 · Cited by 39 · see citing works
Xie, S., Galimberti, F., Olmastroni, E., Carugo, S., Catapano, A. L., & Casula, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120420 · Cited by 35 · see citing works
Durlach, V., Bonnefont‐Rousselot, D., Boccara, F., Varret, M., Filippo, M. D., Cariou, B., Valéro, R., Charrière, S., Farnier, M., Morange, P., et al. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2021.10.009 · Cited by 35 · see citing works
Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease
Gencer, B., & Mach, F. (2020) · Drugs · doi:10.1007/s40265-019-01243-5 · Cited by 34 · see citing works
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
Kosmas, C. E., Bousvarou, M. D., Papakonstantinou, E. J., Tsamoulis, D., Koulopoulos, A., Uceta, R. E., Guzman, E., & Rallidis, L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713622 · Cited by 34 · see citing works
Lipoprotein (a): When to Measure and How to Treat?
Rhainds, D., Brodeur, M. R., & Tardif, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00951-2 · Cited by 32 · see citing works
Youssef, A., Clark, J. R., Marcovina, S. M., Boffa, M. B., & Koschinsky, M. L. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317335 · Cited by 33 · see citing works
Self-citationUnderstanding the ins and outs of lipoprotein (a) metabolism
Boffa, M. B., & Koschinsky, M. L. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000823 · Cited by 34 · see citing works
Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?
Tsioulos, G., Kounatidis, D. C., Vallianou, N. G., Poulaki, A., Kotsi, E., Christodoulatos, G. S., Tsilingiris, D., Karampela, Ι., Skourtis, A., & Dalamaga, Μ. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063537 · Cited by 34 · see citing works
Lipoprotein(a) in clinical practice: New perspectives from basic and translational science
Scipione, C. A., Koschinsky, M. L., & Boffa, M. B. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1415866 · Cited by 33 · see citing works
Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies
Handhle, A., Viljoen, A., & Wierzbicki, A. S. (2021) · Vascular Health and Risk Management · doi:10.2147/vhrm.s266244 · Cited by 31 · see citing works
Biology, pathophysiology and current therapies that affect lipoprotein (a) levels
Rawther, T., & Tabet, F. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.04.005 · Cited by 31 · see citing works
Matveyenko, A., Matienzo, N., Ginsberg, H. N., Nandakumar, R., Seid, H., Ramakrishnan, R., Holleran, S., Thomas, T. A., & Reyes‐Soffer, G. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100336 · Cited by 24 · see citing works
Self-citationPathophysiology, emerging techniques for the assessment and novel treatment of aortic stenosis
Shah, S. M., Shah, J., Lakey, S., Garg, P., & Ripley, D. P. (2023) · Open Heart · doi:10.1136/openhrt-2022-002244 · Cited by 27 · see citing works
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, W., Barbagelata, L., Lobo, M., Nogueira, J. P., & Handelsman, Y. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.12.016 · Cited by 23 · see citing works
Wang, Z., Li, M., Li, J., & Liu, N. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.09.010 · Cited by 23 · see citing works
Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?
Filippatos, T. D., Kei, A. A., & Elisaf, M. (2017) · Diseases · doi:10.3390/diseases5040021 · Cited by 22 · see citing works
Unravelling lipoprotein metabolism with stable isotopes: tracing the flow
Ying, Q., Chan, D. C., Barrett, P. H. R., & Watts, G. F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154887 · Cited by 21 · see citing works
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Koschinsky, M. L., Stroes, E. S. G., & Kronenberg, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106843 · Cited by 22 · see citing works
Vuorio, A. F., Watts, G. F., & Kovanen, P. T. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx546 · Cited by 20 · see citing works
Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration
Ramos-Cáceres, M., Lamíquiz-Moneo, I., Cenarro, A., Calmarza, P., Marco-Benedí, V., Bea, A. M., Mateo‐Gállego, R., Puzo, J., Ordovás, J. M., Civeira, F., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac412 · Cited by 19 · see citing works
New Insights into Pathophysiology and New Risk Factors for ACS
Nardin, M., Verdoia, M., Laera, N., Cao, D., & Luca, G. D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082883 · Cited by 20 · see citing works
Yu, C., Bakshi, A., Watts, G. F., Renton, A. E., Fulton‐Howard, B., Goate, A., Natarajan, P., Chasman, D. I., Robman, L. D., Woods, R. L., et al. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.031459 · Cited by 19 · see citing works
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 19 · see citing works
Therapeutic management of hyperlipoproteinemia (a)
Kosmas, C. E., Sourlas, A., Mallarkey, G., Silverio, D., Garcia, D. Y., Montan, P. D., Guzman, E., & Garcia, M. J. (2019) · Drugs in Context · doi:10.7573/dic.212609 · Cited by 17 · see citing works
Sucato, V., Ortello, A., Comparato, F., Novo, G., & Galassi, A. R. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13071882 · Cited by 15 · see citing works
LP(a): The new marker of high cardiovascular risk
Averna, M. R., & Cefalu, A. B. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103845 · Cited by 14 · see citing works
Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population
Hussain, Z. B., Iqbal, J., Liu, H., & Zhou, H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123586 · Cited by 13 · see citing works
Self-citationFarina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 13 · see citing works
Costanzo, A. D., Indolfi, C., Franzone, A., Esposito, G., & Spaccarotella, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914939 · Cited by 16 · see citing works
Sucato, V., Comparato, F., Ortello, A., Galassi, A. R., & Novo, G. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14050460 · Cited by 12 · see citing works
“CETP inhibitors, like anacetrapib, have shown promise in reducing Lp(a) levels, primarily through diminishing apo(a) production [17].”
BackgroundMitsuda, T., Uemura, Y., Ishii, H., Tanaka, A., Takemoto, K., Koyasu, M., Ishikawa, S., Shibata, R., Watarai, M., & Murohara, T. (2019) · Coronary Artery Disease · doi:10.1097/mca.0000000000000798 · Cited by 12 · see citing works
Fras, Z. (2019) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2019.56068 · Cited by 12 · see citing works
Nicholls, S. J., Nelson, A. J., Ditmarsch, M., Kastelein, J. J. P., Ballantyne, C. M., Ray, K. K., Návar, A. M., Nissen, S. E., Goldberg, A. C., Brunham, L. R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04179-4 · Cited by 12 · see citing works
Lipoprotein(a)-lowering therapies: a promising future
Zhang, J., Návar, A. M., & Tokgözoğlu, L. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag092 · Cited by 11 · see citing works
Interaction Between Lipoprotein(a) and Other Lipid Molecules: A Review of the Current Literature
Sheashaa, H., Mousa, H., Abbas, M. T., Farina, J., Awad, K., Pereyra, M., Scalia, I. G., Ali, N. B., Javadi, N., Bismee, N. N., et al. (2025) · Biomolecules · doi:10.3390/biom15020162 · Cited by 10 · see citing works
Zhou, J., Zhang, Q., Wang, Y., Gao, P., & Chen, D. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1401421 · Cited by 10 · see citing works
Pharmacotherapy for children with elevated levels of lipoprotein(a): future directions
de Boer, L. M., Wiegman, A., Swerdlow, D. I., Kastelein, J. J. P., & Hutten, B. A. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2118522 · Cited by 10 · see citing works
Lipoprotein(a) and Venous Thromboembolism: Association, Causality, and Medications
Pfeferman, M. B., Rashedi, S., Lip, G. Y. H., Weber, C., O’Donoghue, M. L., Nissen, S. E., Nicholls, S. J., Natarajan, P., Plutzky, J., Libby, P., et al. (2025) · Thrombosis and Haemostasis · doi:10.1055/a-2674-5114 · Cited by 9 · see citing works
Association of free-living diet composition with plasma lipoprotein(a) levels in healthy adults
Matveyenko, A., Seid, H., Kim, K., Matienzo, N., Ramakrishnan, R., Thomas, T., & Reyes‐Soffer, G. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01884-2 · Cited by 8 · see citing works
Self-citationAnacetrapib as a potential cardioprotective strategy
Bartolo, B. A. D., & Nicholls, S. J. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114104 · Cited by 8 · see citing works
Lower LDL is better – can this be achieved with CETP inhibition therapy?
Rashid, S. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1715797 · Cited by 7 · see citing works
Emara, A., Gadelmawla, A. F., Awashra, A., Rifai, M. K., Elgendy, M. S., Diaa, A., Emara, M. R., Odat, R. M., Assaassa, A., & Shubietah, A. R. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70316 · Cited by 6 · see citing works
Paragh, G., Zilahi, P., Kolozsvári, L. R., Lőrincz, H., Fülöp, P., & Harangi, M. (2024) · Life · doi:10.3390/life14030374 · Cited by 6 · see citing works
Cruz‐Bautista, I., Flores-Jurado, Y., Álvarez, G. R., Salas-Aldana, M., Elías-López, D., Hernández-Franco, R. F., Rosales-Uvera, S. G., Vargas‐Vázquez, A., Valdez-Echeverría, R. D., Velasco, S. L. D. V., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02610-w · Cited by 5 · see citing works
Supporting evidence for lipoprotein(a) measurements in clinical practice
Matveyenko, A., Pavlyha, M., & Reyes‐Soffer, G. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101746 · Cited by 6 · see citing works
Self-citationCETP Inhibitors: Back With a New Target
Nicholls, S. J., Ray, K. K., Nelson, A. J., & Kastelein, J. J. P. (2026) · Circulation Research · doi:10.1161/circresaha.125.327271 · Cited by 4 · see citing works
Influencia de la concentración de triglicéridos en la lipoproteína(a) en función de la dislipidemia
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Calmarza, P., Bea, A. M., Vila, À., Morillas, C., Puzo, J., García, J. D. M., Alamán, A. I. F., et al. (2023) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2023.11.005 · Cited by 4 · see citing works
Groenen, A. G., Matveyenko, A., Matienzo, N., Halmos, B., Zhang, H., Westerterp, M., & Reyes‐Soffer, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117474 · Cited by 4 · see citing works
Self-citationDron, J. S., Lazarte, J., & Hegele, R. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311581 · Cited by 4 · see citing works
Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.
Engler, R. J. M., Brede, E., Villines, T. C., & Vernalis, M. (2019) · PubMed Central · Cited by 3 · see citing works
Lipoprotein(a): structural basis, bidirectional risk, and therapeutic frontiers
Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.25-94 · Cited by 2 · see citing works
Study of effect modifiers of genetically predicted CETP reduction
Legault, M., Barhdadi, A., Gamache, I., Lemaçon, A., Perreault, L. L., Grenier, J., Sylvestre, M., Hussin, J., Rhainds, D., Tardif, J., et al. (2023) · Genetic Epidemiology · doi:10.1002/gepi.22514 · Cited by 2 · see citing works
Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a)
Kayıkçıoğlu, M., Özkan, H. S., & Tokgözoğlu, L. S. (2023) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i3.21 · Cited by 2 · see citing works
Influence of triglyceride concentration in lipoprotein(a) as a function of dyslipidemia
Marco-Benedí, V., Cenarro, A., Laclaustra, M., Calmarza, P., Bea, A. M., Vila, À., Morillas, C., Puzo, J., García, J. D. M., Alamán, A. I. F., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2024.03.001 · Cited by 2 · see citing works
Zhang, K., Li, J., Li, Y., Yan, K., Zhu, P., Tang, X., Yuan, D., Yang, Y., Gao, R., Yuan, J., et al. (2024) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296241280711 · Cited by 2 · see citing works
Cesaro, A., Scherillo, G., Michele, G. D., Acerbo, V., Signore, G., Panico, D., Porcelli, G., Scialla, F., Raucci, G., Rotolo, F. P., et al. (2024) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2023.35 · Cited by 1 · see citing works
Obicetrapib and CETP inhibition: An exception to the rule?
Cariou, B., & Moulin, P. (2025) · Med · doi:10.1016/j.medj.2025.100780 · Cited by 1 · see citing works
Lipoprotein(a): Metabolism, Pathophysiology, and Impact on Diabetes Mellitus
Kostner, K., & Kostner, G. M. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_10 · Cited by 1 · see citing works
Tada, H., Furukawa, A., Kojima, N., Usui, S., Sakata, K., Kawashiri, M., & Takamura, M. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120417 · Cited by 1 · see citing works
Therapy of Elevated Lipoprotein(a)
Ibrahim, S., & Stroes, E. S. G. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_21 · Cited by 1 · see citing works
Khalaf, R. A., Sabbah, D., Al‐Shalabi, E., Ikhmais, B., Naser, W., & Albadawi, G. (2022) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1045
Contemporary Aspects of Lp(a) Metabolism and Therapies Based on Tracer Kinetic Studies in Humans
Chan, D. C., Pang, J., & Watts, G. F. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_5
Millar, J. S., & Rader, D. J. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-24575-6_4
Self-citationEspoirs et place prochaine potentielle des inhibiteurs de la Lp(a)
Guédon, A. F., Ghrenassia, E., Cohen, A. A., & Boccara, F. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.01.003
Lp(a). Lo que sabemos, lo que desconocemos y lo que esperamos
Moyá-Amengual, A., & Serrano-Cumplido, A. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102451
Matveyenko, A., Seid, H., Kim, K., Ramakrishnan, R., Thomas, T., Matienzo, N., & Reyes‐Soffer, G. (2023) · Figshare · doi:10.6084/m9.figshare.24091783
Self-citationApproches biochimique, épidémiologique et clinique du métabolisme intégré de la Lipoprotéine (a)
Blanchard, V. (2020) · theses.fr (ABES) · doi:10.70675/3ce7e0fdzecbaz4b18zaf08z34fb33c163ff
Chemello, K. (2022) · theses.fr (ABES) · doi:10.70675/6f647f12za09bz494fzae02z9be71ebf2915
Animati, F. M., Proietti, S., Auletta, F., Montone, R. A., Cappannoli, L., Fracassi, F., Gaspardone, A., & Burzotta, F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15155897
Granata, L. G., Giubilato, S., Campanella, F., Amico, F., Fusco, S. A. D., & Colivicchi, F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1886347
Rosso, L. A. G., Botta, E., Pierini, F. S., Martín, M., Sáez, M. S. C., Davico, B., Cerda, O., Citera, G., Gandino, I. J., Rosa, J., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.08.018
- Authors
- Thomas, T., Zhou, H., Karmally, W., Ramakrishnan, R., Holleran, S., Liu, Y., Jumes, P., Wagner, J. A., Hubbard, B., Previs, S. F., Roddy, T., Johnson-Levonas, A. O., Gutstein, D. E., Marcovina, S. M., Rader, D. J., Ginsberg, H. N., Millar, J. S., & Reyes-Soffer, G.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- From the Columbia University, New York (T.T., W.K., R.R., S.H., H.N.G., G.R.-S.); Merck & Co, Inc, Kenilworth, NJ (H.Z., Y.L., P.J., J.A.W., B.H., S.F.P., T.R., A.O.J.-L., D.E.G.); University of Washington, Seattle (S.M.M.); and University of Pennsylvania, Philadelphia (D.J.R., J.S.M.).
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2017-09
- Volume
- 37
- Issue
- 9
- Pages
- 1770-1775
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC5567403
- OpenAlex
- W2736338239
- Cited by
- 96
- References
- 36
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 13 · 2023: 19 · 2022: 14 · 2021: 8 · 2020: 4 · 2019: 8 · 2018: 7 · 2017: 8
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- Sanofi
- Regeneron Pharmaceuticals
- Kowa Company
- National Institutes of Health (KL2TR000081)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- anacetrapib, CETP inhibition, lipoprotein(a), apolipoprotein B, HDL metabolism, atorvastatin, hypercholesterolemia, cardiovascular risk factors, aortic stenosis
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Chromatography, Liquid, Double-Blind Method, Female, Humans, Hypercholesterolemia, Male, Middle Aged, New York City, Pennsylvania, Severity of Illness Index, Time Factors, Biomarkers, Down-Regulation, Treatment Outcome, Lipoprotein(a), Oxazolidinones, Cholesterol Ester Transfer Proteins, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
